Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.
| Autor: | Herman AG; Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10027, USA., Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C, Stockwell BR |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer discovery [Cancer Discov] 2011 Sep; Vol. 1 (4), pp. 312-25. Date of Electronic Publication: 2011 Jul 28. |
| DOI: | 10.1158/2159-8290.CD-11-0104 |
| Abstrakt: | E3 ubiquitin ligases are of interest as drug targets for their ability to regulate protein stability and function. The oncogene Mdm2 is an attractive E3 ligase to target, as it is the key negative regulator of the tumor suppressor p53, which controls the transcription of genes involved in cell fate. Overexpression of Mdm2 facilitates tumorigenesis by inactivating p53, and through p53-independent oncogenic effects. We developed a high-throughput cellular Mdm2 auto-ubiquitination assay, which we used to discover a class of small-molecule Mdm2 ligase activity inhibitors. These compounds inhibit Mdm2 and p53 ubiquitination in cells, reduce viability of cells with wild-type p53, and synergize with DNA-damaging agents to cause cell death. We determined that these compounds effectively inhibit the E3 ligase activity of the Mdm2-MdmX hetero-complex. This mechanism may be exploitable to create a new class of anti-tumor agents. (©2011 AACR.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|